( nued and hydration forseveral days is ...)Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO,Health

nued and hydration for several days is recommended.
Please see accompanying full Prescribing Information in the Package Insert or on the Ganite
website at www.ganite.com.

About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is
focused on delivering innovative products for the treatment of patients with cancer. The
Company’s research platform is anchored by two major programs that center on oligonucleotides
(RNA- and DNA- based medicines) and small molecules. Genasense® (oblimersen sodium)
Injection is the Company's lead compound from its oligonucleotide program. The leading drug
in Genta’s small molecule program is Ganite® (gallium nitrate injection), which the Company is
exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related
hypercalcemia that is resistant to hydration. Genta is partnered with IDIS
(www.idispharma.com) on a program whereby both Ganite® and Genasense® are available on a
“named-patient” basis in countries outside the United States. For more information about Genta,
please visit our website at: www.genta.com.

Safe Harbor
This press release may contain forward-looking statements with respect to business conducted by
Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and
uncertainties because they relate to events and depend on circumstances that will occur in the
future. Forward-looking statements include, without limitation, statements about:
• the Company’s ability to obtain necessary regulatory approval for Genasense® from the
U.S. Food and Drug Administration (“F
'"/>




Page: 1 2 3 4 5
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery